✨ Free AI Report
KALA BIO, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research KALA BIO, Inc.
Company Research

KALA BIO, Inc.: Business Overview, Financials & Competitive Analysis

KALA BIO, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Distressed clinical-stage biotech with speculative upside contingent on KPI-012 Phase 2b success, but challenged by capital constraints and steep stock decline. The company has a market cap of approximately $10.3M, indicating severe capital constraints. The stock has declined 94.42% over the past year, reflecting significant shareholder value destruction. As.

What is KALA BIO, Inc.'s industry? KALA BIO, Inc. (kalarx.com) operates in Biopharmaceuticals - Ophthalmology/Rare Diseases. AskCyborg classifies KALA BIO, Inc. under Biopharmaceuticals - Ophthalmology/Rare Diseases in its company registry.

KALA BIO, Inc. is a clinical-stage biopharmaceutical company engaged in the research, development, and commercialization of therapies for rare and severe eye diseases. The company focuses on the development and commer...

3/ 10Challenged

Cyborg Score thesis

Distressed clinical-stage biotech with speculative upside contingent on KPI-012 Phase 2b success, but challenged by capital...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Ophthalmology/Rare Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest KALA BIO, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for KALA BIO, Inc.

AskCyborg analysts argue the bull and bear cases for KALA BIO, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
KALA BIO, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

KALA BIO, Inc. Overview

Pro stress-test →

KALA BIO, Inc. is a clinical-stage biopharmaceutical company engaged in the research, development, and commercialization of therapies for rare and severe eye diseases. The company focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles.

Strategic Profile

Pro stress-test →

The company's lead product candidate, KPI-012, is in Phase 2b clinical trial for treatment of persistent corneal epithelial defects and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company maintains a focused pipeline on ophthalmic indications with specialized drug delivery technology.

Competitive Landscape

Pro stress-test →

KALA BIO operates in the rare ophthalmologic disease space with limited direct competitors for specific indications. The company competes broadly against larger pharma with ophthalmic portfolios (Allergan, Bausch & Lomb) and specialized biotech focused on rare eye diseases. KALA's nanoparticle technology provides differentiation but faces adoption and capital challenges.

Industry Context

KALA BIO, Inc. operates in Biopharmaceuticals - Ophthalmology/Rare Diseases.

Key facts

Founded: 2009 · Headquarters: Arlington, Massachusetts · Employees: 38 · Revenue: N/A · Market cap: $10.3M

What the analysts stress-tested

The top findings that survived the multi-agent debate for KALA BIO, Inc..

  • Market cap of $10.3M indicates severe capital constraints for a clinical-stage biotech company
  • Stock has declined 94.42% over the past year with extreme volatility (52-week range $0.36 to $20.60)
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Dec 2025Announced purchase agreements for aggregated assets
  • Feb 2026Trading near all-time lows at $0.363, down from $20.60 high in 52-week range
  • +1 moreTrack every material event for KALA BIO, Inc. as it happens. Explore monitoring →
Get alerted when KALA BIO, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ophthalmic PortfolioEstablished ophthalmic pharmaceutical portfolio with broad disease coverage→Retinal Disease FocusLarge pharma with inherited retinal disease programs→Rare Eye DiseaseMultiple small-cap companies competing in rare ophthalmic indications→

Compare KALA BIO, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

KALA BIO, Inc. operates in Biopharmaceuticals - Ophthalmology/Rare Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Ophthalmology/Rare Diseases research →
NEW · MCP server

Ask your AI assistant about KALA BIO, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare KALA BIO, Inc. and its top competitor on Cyborg Score”
“What did KALA BIO, Inc. do this quarter?”
“Is KALA BIO, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does KALA BIO, Inc. do?+
KALA BIO, Inc. is a clinical-stage biopharmaceutical company engaged in the research, development, and commercialization of therapies for rare and severe eye diseases. The company focuses on the development and commer...
What is KALA BIO, Inc.'s Cyborg Score?+
KALA BIO, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are KALA BIO, Inc.'s main competitors?+
Named competitors include Ophthalmic Portfolio, Retinal Disease Focus, Rare Eye Disease. The full competitive landscape is in the AskCyborg report.
How can I get the full KALA BIO, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the KALA BIO, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track KALA BIO, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Ophthalmology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Belite Bio, Inc5Kodiak Sciences Inc.2Opthea Limited